Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00085150 | LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00002765 | Immunotoxin in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00003993 |
| Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma |
| completed |
| Phase 1 |
| 24 |
| National Institute on Aging (NIA)NIH |
| 1 |
| Apr 29, 2015 |
| clinicaltrials |
| NCT00019318 | Depsipeptide in Treating Patients With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019344 | Flavopiridol in Treating Patients With Refractory Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019656 | Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00019838 | UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00020111 | Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 3 | Apr 29, 2015 | clinicaltrials |
| NCT00506922 | Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT | completed | Phase 1 / Phase 2 | 150 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00771472 | Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01065025 | Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies(AEGIS) | completed | Phase 1 | 60 | 4SC AGINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00049400 | S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction | completed | Phase 1 | 78 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 3, 2015 | clinicaltrials |
| NCT00426855 | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) | completed | Phase 1 / Phase 2 | 12 | Peter MoosmannOTHER | 0 | Apr 3, 2015 | clinicaltrials |
| NCT00735930 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00244946 | Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00694590 | Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00864942 | Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)(Phase I BLR) | completed | Phase 1 | 28 | Georgetown UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT00352443 | S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 66 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00967044 | Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma | completed | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 26, 2015 | clinicaltrials |
| NCT00221325 | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | completed | Phase 1 | 14 | University of California, San FranciscoOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00416923 | Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma | completed | Phase 1 | 10 | University of California, San FranciscoOTHER | 0 | Feb 16, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01650727 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | completed | Phase 1 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 10, 2015 | clinicaltrials |
| NCT00060684 | Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma | completed | Phase 1 | 30 | CTI BioPharmaINDUSTRY | 1 | Jan 19, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 | clinicaltrials |
| NCT00274742 | Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | completed | Phase 1 | 76 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 16, 2015 | clinicaltrials |
| NCT00323934 | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jan 8, 2015 | clinicaltrials |
| NCT00078637 | Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma | completed | Phase 1 | 37 | Eisai Inc.INDUSTRY | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00082784 | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | completed | Phase 1 | 93 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01330173 | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00079716 | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | completed | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00103779 | A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma | completed | Phase 1 | 50 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00430846 | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | completed | Phase 1 | 45 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00655837 | Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL | completed | Phase 1 | 33 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01015911 | A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma | completed | Phase 1 | 58 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01026415 | Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 73 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | completed | Phase 1 | 51 | Seagen Inc.INDUSTRY | 2 | Dec 18, 2014 | clinicaltrials |
| NCT01026233 | Cardiac Safety Study of Brentuximab Vedotin (SGN-35) | completed | Phase 1 | 52 | Seagen Inc.INDUSTRY | 2 | Dec 12, 2014 | clinicaltrials |
| NCT00968656 | Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1(FISO PET/CT) | completed | Phase 1 | 31 | Washington University School of MedicineOTHER | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01561911 | A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 7/4 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | completed | Phase 1 | 29 | Cancer Research UKOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00991562 | IMGN901 in Combination With Lenalidomide and Dexamethasone | completed | Phase 1 | 50 | ImmunoGen, Inc.INDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | completed | Phase 1 | 30 | Cellerant TherapeuticsINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support | completed | Phase 1 | 25 | Swedish Orphan BiovitrumINDUSTRY | 0 | Oct 24, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Apr 30, 2015source: clinicaltrials